Monday, December 23

Tag: Immunizations

The Covid Vaccine Windfall Turns for Pfizer and Moderna
19Nov By adminNo Comments
World

The Covid Vaccine Windfall Turns for Pfizer and Moderna

Updated Nov. 19, 2023 3:03 pm ETThe U.S. was in a fit of Covid panic during Thanksgiving week two years ago. The Omicron variant had emerged like a creature from the Black Lagoon. Public-health officials indicated we’d need another updated booster. Share prices in Pfizer and Moderna surged. By month’s end, Pfizer’s stock-market value had surpassed $300 billion, up 50% from the start of the pandemic. Moderna’s shares had soared by more than 1,000% over the same period. In 2022 Pfizer became the first pharmaceutical company to book more than $100 billion in annual sales owing to government purchases of its vaccines and antiviral pill.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
When to Get Your Covid Booster, Flu Vaccine or RSV Shot This Fall
1Nov By adminNo Comments
World

When to Get Your Covid Booster, Flu Vaccine or RSV Shot This Fall

Updated Nov. 1, 2023 12:57 pm ETAmericans have started rolling up their sleeves for an array of shots to help stem the anticipated tide of respiratory infections this season. So far, it’s been a bumpy ride.Most people should be able to get updated Covid-19 shots free, but the process is more convoluted now that the public health emergency has ended. Still, now is the time to take advantage of the Covid-19 vaccine and all other available shots, doctors and officials said.  Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
GSK PLC Raises Guidance After RSV Vaccine Lifts Earnings
1Nov By adminNo Comments
World

GSK PLC Raises Guidance After RSV Vaccine Lifts Earnings

Updated Nov. 1, 2023 4:08 am ETGSK PLC raised its guidance after third-quarter net profit rose mainly due to the U.S. launch of its Arexvy vaccine, although it missed analysts’ forecasts.The British pharmaceutical giant said Wednesday that net profit from continuing operations for the third quarter was 1.46 billion pounds ($1.77 billion), boosted by the vaccine for respiratory syncytial virus, or RSV, compared with GBP759 million a year earlier and a company-compiled consensus of GBP1.87 billion.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More